Endocrine Abstracts

Introduction: Pancreatic neuroendocrine tumors (panNETs) are often inoperable at diagnosis. The mTORC1 inhibitor everolimus is approved for the treatment of advanced NETs. Unfortunately, the development of resistance against everolimus limits its clinical efficacy.Aim: Our aim was to establish an everolimus-resistant panNET cell line to find common mechanisms of resistance.Methods: Pancreatic neuroendocrine tumor cells (BON1) were ...

Cyclin-dependent kinases (CDKs) are crucial for the cell cycle regulation and alterations of the cell cycle and its regulators are often observed in human malignancies. CDK4/6 in particular orchestrates the G1 phase progression and the G1/S transition. Here we investigated the in vitro effects of the CDK4/6 inhibitor LEE001(Novartis, Basel) on the human neuroendocrine tumor (NET) cell lines BON1, QGP1 and NCI-H727. The cells were treated with different concentrations ...

Introduction: Primary aldosteronism (PA) is the most frequent form of endocrine hypertension and is commonly caused by an aldosterone producing adenoma (APA). Germline and somatic mutations in the KCNJ5 gene have been found in up to 40% of APAs and demonstrated to play a crucial role in the pathophysiology of PA.Aim: Here we characterize and investigate the effects of the most common KCNJ5 mutations on cellular death mechanisms based on...

Introduction: In our previous studies we found that the combination of 13-cis retinoic acid (13cRA) and lovastatin significantly reduced tumour growth in a mouse phaeochromocytoma allograft model, with the lowest microvessel density in the combination-treated tumours. We have now investigated the effect of 13cRA plus lovastatin on neuroendocrine (BON1, H727) and non-endocrine tumour (HepG2, Huh7) cell viability and signalling pathways (EGFR, AKT, ERK, p70S6K) to eluci...